Camille L Bedrosian's Net Worth
$7.93 Million
Who is Camille L Bedrosian?
Camille L Bedrosian has an estimated net worth of $7.93 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., Crinetics Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., ARIAD PHARMACEUTICALS INC, and Amylyx Pharmaceuticals, Inc..
SEC CIK
Camille L Bedrosian's CIK is 0001326969
Past Insider Trading and Trends
2021 was Camille L Bedrosian's most active year for acquiring shares with 9 total transactions. Camille L Bedrosian's most active month to acquire stocks was the month of May. 2021 was Camille L Bedrosian's most active year for disposing of shares, totalling 12 transactions. Camille L Bedrosian's most active month to dispose stocks was the month of December. 2021 saw Camille L Bedrosian paying a total of $1,925,000.00 for 88,636 shares, this is the most they've acquired in one year. In 2021 Camille L Bedrosian cashed out on 77,509 shares for a total of $5,538,559.36, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
RHYTHM PHARMACEUTICALS, INC. (RYTM) Snapshot price: $49.25
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 3K |
—
|
—
| 3K |
Jun 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 9
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Crinetics Pharmaceuticals, Inc. (CRNX) Snapshot price: $50.39
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +56.67% | 3.4K |
—
|
—
| 9.4K |
Jun 7
| |||
Form 4
|
∞
| 6K |
—
|
—
| 6K |
Jun 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Ultragenyx Pharmaceutical Inc. (RARE) Snapshot price: $55.24
EVP and Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -2.54% | -1.22K |
$45.25 | -$175,615.25 | 46.72K |
Mar 1
| |||
Form 4
| +30.41% | 11.18K |
$66.62 | -$187,935.02 | 47.94K |
Mar 1
| |||
Form 4
| -4.31% | -1.66K |
$66.30 | -$109,859.10 | 36.76K |
Jan 30
| |||
Form 4
| -0.93% | -359.00 |
$81.14 | -$29,129.26 | 38.42K |
Oct 14
| |||
Form 4
|
—
|
0
|
$77.56 | -$225,525.00 | 38.77K |
Scheduled
|
Sep 1 - Sep 2
| ||
Form 4
| -0.93% | -364.00 |
$113.67 | -$41,375.88 | 38.77K |
May 6
| |||
Form 4
|
—
|
0
|
$82.05 | -$270,450.00 | 39.14K |
Scheduled
|
Apr 15
| ||
Form 4
| +16.67% | 5.59K |
$138.18 | -$627,751.74 | 39.14K |
Mar 1
| |||
Form 4
| -6.27% | -2.24K |
$140.36 | -$314,827.48 | 33.55K |
Jan 30
| |||
Form 4
|
—
|
0
|
$97.09 | -$2,104,500.00 | 35.79K |
Scheduled
|
Jan 15
| ||
Form 4
| -0.73% | -262.00 |
$88.00 | -$23,056.00 | 35.79K |
Oct 14
| |||
Form 4
| -0.69% | -249.00 |
$66.26 | -$16,498.74 | 36.05K |
May 6
| |||
Form 4
| +47.47% | 11.69K |
$56.08 | -$70,043.92 | 36.3K |
Mar 1
| |||
Form 4
| -6.19% | -1.62K |
$53.23 | -$86,445.52 | 24.61K |
Jan 30
| |||
Form 4
| +5.79% | 1.44K |
—
|
—
| 26.24K |
Oct 14
| |||
Form 4
| +6.15% | 1.44K |
—
|
—
| 24.8K |
May 6
| |||
Form 4
| +42.78% | 7K |
—
|
—
| 23.36K |
Mar 1
| |||
Form 4
| -9.09% | -1.64K |
$48.85 | -$79,918.60 | 16.36K |
Jan 30
| |||
Form 4
|
∞
| 18K |
—
|
—
| 18K |
Jan 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ARIAD PHARMACEUTICALS INC No price found
VP, Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Amylyx Pharmaceuticals, Inc. (AMLX) Snapshot price: $2.37
Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +166.13% | 96.91K |
—
|
—
| 155.24K |
Apr 16
| |||
Form 4
|
∞
| 58.33K |
—
|
—
| 58.33K |
Nov 27
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||